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Glucagonoma syndrome consists of the tumour of 
pancreatic alpha cells and symptoms caused by the 
abnormal glucagon production. A hallmark sign of this 
syndrome is necrolytic migratory erythema (NME) first 
described in 1942 [1]. Its distinctive clinical appearance 
along with concomitant diabetes mellitus, weight loss, 
deep vein thrombosis, neuropsychiatric disorders and 
diarrhoea may suggest the diagnosis. Treatment is cura-
tive if the early diagnosis is made and involves tumour 
surgical resection [2, 3].
A 49-year-old woman was admitted to the Derma-
tology Department with a skin rash possibly preceded 
by drug intake (acetylsalicylic acid, ibuprofen) due to 
the upper respiratory tract infection. Herpes simplex 
viral (HSV) infection history was negative. On physical 
examination she presented diffuse round erythematous 
macules, some of them creating targetoid lesions, over 
the neck (Figure 1 B), trunk (Figure 1 C), thighs and elbows 
along with acral symmetric cellulitis and painful blisters 
on the dorsal and palmar surfaces (Figure 1 A). Paro-
nychia of almost all fingers was observed. There were 
small erosions in oral mucosa. The hair and nails were 
not affected. The patient was obese (BMI 30.5 kg/m2) and 
diagnosed with mild diabetes 4 months earlier. The fam-
ily history was negative for dermatological diseases and 
unremarkable for other conditions. 
Laboratory investigations revealed lymphocytosis 
51.5% (20–40%), hyperglycaemia 6.34 mmol/l (3.9–5.5) 
and erythrocyte sedimentation rate (ESR) 48 mm/h. Oth-
er tests including biochemistry, renal and hepatic profile, 
thyroid function tests, IgE, ASO were normal. Hepatitis B 
virus (HBV) and HCV serology were negative. Imaging ex-
aminations (chest X-ray and abdominal ultrasonography) 
were within normal limits. Histopathological examination 
could be consistent with drug reaction (Figure 2 A). She 
was diagnosed with erythema multiforme and treated 
with steroids (dexamethasone intramuscular followed 
by methylprednisolone per os) and clarithromycin with 
good response.
After 2 months the patient was readmitted to our De-
partment due to the worsening of the skin condition. The 
physical examination revealed erythematous papules 
and crusted patches predominantly involving the inter-
triginous regions and scattered over the trunk (Figures 
3 A–C). The lesions spread outward leaving postinflam-
matory hyperpigmentation. The patient reported pruritus 
and persistent angular cheilitis. Laboratory tests showed 
an elevated glucose level of 10.49 mmol/l with no other 
abnormalities. Another skin biopsy was performed and 
revealed epidermal prominent parakeratosis, mild acan-
thosis and spongiosis. Perivascular and focal mild infil-
tration of lymphocytes, histiocytes, neutrophils and eo-
sinophils was observed in the upper dermis (Figure 2 B). 
The clinical differentials at that time were: psoriasis, pity-
riasis rubra pilaris, eczema and allergic contact dermati-
tis. She was treated sequentially with phototherapy (UVB 
311 nm) and acitretin 30 mg daily with a rapid exacerba-
tion of skin lesions. 
Taking into account an unusual clinical picture and 
undiagnostic histopathological results, the paraneoplastic 
syndrome was suspected. The second abdominal ultra-
sonography disclosed round lesions in the liver – 24 mm 
in the right lobe and 21 mm in the left lobe. A contrast-
enhanced computed tomography of the abdomen con-
firmed multiple hepatic tumours and low enhancing 
pancreatic tail mass 56 × 37 mm (Figure 4). The serum 
glucagon level was highly elevated 2275 ng/l (norm 
< 209) as well as the levels of chromogranin A 17.2 ng/ml 
(0–6) and LDH 224 U/l (100–214). She was referred to 
the Oncology Department where she underwent a needle 
biopsy of a hepatic lesion that confirmed the neuroen-
docrine tumour diagnosis (NET G2, Ki-67 3%) with the 
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primary tumour in the pancreas. Afterwards the patient 
was referred to the Endocrinology Department where she 
started lanreotide injections of 120 mg once a month. 
The surgical removal of the tumour was not performed 
due to the patient’s refusal. For the last 12 months the 
disease has remained stable.
Glucagonomas are rare neuroendocrine tumours with 
the incidence rate of 1 in 20 million people with an in-
creasing occurrence in recent decades [4–6]. They can 
be associated with multiple endocrine neoplasia type 1 
(MEN1) in up to 10% but most often are sporadic [7]. They 
occur mostly in people in their 5th decade of life, equally 
in males and females, although a case of the paediatric 
patient was also reported [2, 7].
Glucagon produced by the tumour leads to different 
symptoms the most characteristic of which is NME pres-
ent in up to 67% of patients [8]. The clinical presentation 
involves pruritic erythematous macules that become 
necrotic or erythematous vesicles and bullae evolving 
into ulcers and crusted plaques. They affect perineum, 
perioral and intertriginous areas along with legs, feet and 
lower abdomen. Koebner phenomenon can be present 
[9]. Other skin and mucosal changes include paronychia, 
glossitis, cheilitis and angular stomatitis. Aetiology re-
mains unclear however the catabolic effect of hyperglu-
cagonemia causing hypoaminoacidemia, deficiency of 
essential fatty acids and zinc are considered as trigger-
ing factors. NME is not specific to glucagonoma and can 
be found in other diseases (cirrhosis, pancreatitis, other 
malignancies, malabsorption etc.). Other features of glu-
cagonoma include diabetes mellitus (usually mild, con-
trolled with only oral drugs) especially in a patient who 
has had recent weight loss and normochromic anaemia; 
diarrhoea, deep vein thrombosis and neuropsychiatric 
disorders [2, 3, 7]. It is also called 4D syndrome (diabetes, 
dermatosis, deep vein thromboses and depression) [10]. 
Figure 4. Computed tomography (CT) of the abdomen 
showing low enhancing pancreatic tail mass measuring 
56 × 37 mm
Figure 1. Cellulitis and blisters on the dorsal surfaces of the 
feet (A). Erythematous macules and targetoid lesions over 
the neck (B) and trunk (C)
A
B C
Figure 2. Initial biopsy revealed prominent acanthosis and 
parakeratosis with minimal spongiosis and focal apoptotic 
eosinophilic keratinocytes (haematoxylin and eosin; 40× 
magnification) (A). Subsequent biopsy showed irregular 
acanthosis and prominent parakeratosis (with a partially 
homogenous parakeratotic layer). In the papillary dermis, 
focal inflammatory infiltrate composed of lymphocytes, few 
histiocytes, few granulocytes were observed (haematoxylin 
and eosin; 40× magnification) (B)
Figure 3. Erosive, erythematous plaques with crusting and 
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Histologically presence of epidermal pallor (vacuolated 
keratinocytes), focal or confluent epidermal necrosis and 
parakeratosis should suggest the NME although these fea-
tures are nonspecific and can be absent depending on the 
stage of evolution of the biopsied lesion [11].
As the clinical appearance and histopathological find-
ings vary patients often remain misdiagnosed as eczema, 
psoriasis, acrodermatitis enteropathica, zinc deficiency, 
essential fatty acid deficiency, pellagra, side effects of 
certain drugs or the initial stages of bullous disease [2]. 
Patients are waiting for a correct diagnosis for a long 
time, with median time of 39 months in a case series of 
6 patients [12].
By the time of diagnosis tumours usually reach large 
sizes (0.4–25 cm) and are easily detected in conventional 
imaging [13]. Computed tomography scans localize tu-
mour mass in the body or tail of pancreas with contrast 
enhancing due to their hypervascularity [8]. The only cu-
rative treatment is complete surgical removal of primary 
tumour which can be impossible in most cases due to the 
locally advanced stage and liver metastasis (78% at the 
time of diagnosis) [6]. For those patients, palliative sur-
gery or chemotherapy may be considered. Even partial 
resection brings prominent clinical resolution by reducing 
the glucagon level in the blood [14]. Chemotherapy has 
low efficacy as the tumours have an extremely low mi-
totic rate and then chemotherapy is usually replaced by 
long-acting somatostatin analog (lanreotide, octreotide) 
– over 80% of glucagonomas express somatostatin re-
ceptors [14, 15]. Those agents demonstrate antiprolifera-
tive action and reduce glucagon secretion. In the recent 
study lanreotide was proven to significantly prolong pro-
gression-free survival and is recommended for the treat-
ment of patients with gastroenteropancreatic neuroen-
docrine tumours (grade 1 and 2) (Ki-67 proliferative index 
< 10%), regardless of the degree of liver involvement and 
the location of primary tumour [16]. Our patient complied 
with all of these criteria and lanreotide was used with 
good initial response and tolerability, which resulted in 
almost complete resolution of skin lesions. 
In conclusion, increased knowledge of polymorphic 
clinical presentation of necrolytic migratory erythema 
can avoid delay in the recognition. We present a case 
with rapid onset of erythema multiforme-like eruptions 
which evolved over a few months into characteristic fea-
tures of NME facilitating the early diagnosis.
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